Brisbane, Oct. 20 (SANA) Australian biotechnology startup Accretion Bio is preparing to use a University of Queensland-developed platform to advance early-stage drug discovery for Alzheimer’s and Parkinson’s diseases by tracking protein behavior inside living neurons.
The platform, known as NASTIC (Nanoscale Spatiotemporal Indexing Clustering), enables researchers to monitor how individual proteins move, cluster and interact inside living cells and assess how potential drug candidates affect them.
Developed over more than two decades of research at the university’s Queensland Brain Institute, NASTIC has been spun out into Brisbane-based Accretion Bio, with support from the university’s commercialization company UniQuest and backing from venture firm Antler.
Professor Frederic Meunier, who led the research with colleague Dr. Tristan Wallis, said the platform allows scientists to track proteins inside living neurons and observe how potential drug candidates influence their behavior.
Accretion Bio CEO Phillip Craig said the company would work with pharmaceutical and biotechnology partners to apply NASTIC to their research programs while advancing its own drug discovery program focused on neurodegenerative diseases.
The University of Queensland said industry-funded research using the platform was already underway and that it had attracted interest from global pharmaceutical companies. Potential applications could also extend to immunology and oncology, where protein clustering plays a role in cell signaling.
The underlying scientific methodology was described in a paper published in Nature Protocols in August 2025. Accretion Bio is scheduled to present at the Early-Stage Innovation Forum and exhibit in Queensland Startup Alley at AusBiotech 2026 on the Gold Coast from October 21 to 23.
The platform is intended to support early-stage research, but further investigation is needed to establish its contribution to developing effective treatments for Alzheimer’s and Parkinson’s.
R.H/M.F